文献检索，用中文搜 PubMed

Suppr 超能文献

核心技术专利：CN118964589B侵权必究

核心技术专利：CN118964589B侵权必究

Shinyama H, Nagai H, Kawamura T, Narita Y, Nakamura N, Kagitani Y

Research Division, The Green Cross Corporation, Hirakata, Osaka, Japan.

Gen Pharmacol. 1998 Mar;30(3):379-86. doi: 10.1016/s0306-3623(97)00273-5.

The potential of AE0047, a novel calcium antagonist, to remedy brain damage of stroke-prone spontaneously hypertensive rats (SHRSPs) with signs of stroke was compared with those of nicardipine and hydralazine. 2. AE0047 (1 and 3 mg/kg/day) given daily to diseased SHRSPs prevented mortality and improved neurological symptoms. Histological examination also supported the effectiveness of AE0047 against the progression of the disease. 3. Nicardipine (10 mg/kg/day) and hydralazine (10 mg/kg/day) were less effective than AE0047 in a dose equal to or more than the hypotensive dose, respectively. 4. AE0047 may be beneficial for treating the acute stage of stroke in humans by virtue of its long-lasting hypotensive action and undefined direct actions on the cerebral vasculature.

将新型钙拮抗剂AE0047与尼卡地平及肼屈嗪相比，评估其对出现中风症状的易中风自发性高血压大鼠（SHRSPs）脑损伤的治疗潜力。2. 每天给患病的SHRSPs服用AE0047（1毫克/千克/天和3毫克/千克/天）可预防死亡并改善神经症状。组织学检查也证实了AE0047对疾病进展的疗效。3. 尼卡地平（10毫克/千克/天）和肼屈嗪（10毫克/千克/天）在等于或高于降压剂量时，疗效均不如AE0047。4. AE0047因其持久的降压作用以及对脑血管系统的未知直接作用，可能对治疗人类中风急性期有益。

Shinyama H, Nagai H, Kawamura T, Narita Y, Nakamura N, Kagitani Y

Research Division, The Green Cross Corporation, Hirakata, Osaka, Japan.

Gen Pharmacol. 1998 Mar;30(3):379-86. doi: 10.1016/s0306-3623(97)00273-5.

The potential of AE0047, a novel calcium antagonist, to remedy brain damage of stroke-prone spontaneously hypertensive rats (SHRSPs) with signs of stroke was compared with those of nicardipine and hydralazine. 2. AE0047 (1 and 3 mg/kg/day) given daily to diseased SHRSPs prevented mortality and improved neurological symptoms. Histological examination also supported the effectiveness of AE0047 against the progression of the disease. 3. Nicardipine (10 mg/kg/day) and hydralazine (10 mg/kg/day) were less effective than AE0047 in a dose equal to or more than the hypotensive dose, respectively. 4. AE0047 may be beneficial for treating the acute stage of stroke in humans by virtue of its long-lasting hypotensive action and undefined direct actions on the cerebral vasculature.

将新型钙拮抗剂AE0047与尼卡地平及肼屈嗪相比，评估其对出现中风症状的易中风自发性高血压大鼠（SHRSPs）脑损伤的治疗潜力。2. 每天给患病的SHRSPs服用AE0047（1毫克/千克/天和3毫克/千克/天）可预防死亡并改善神经症状。组织学检查也证实了AE0047对疾病进展的疗效。3. 尼卡地平（10毫克/千克/天）和肼屈嗪（10毫克/千克/天）在等于或高于降压剂量时，疗效均不如AE0047。4. AE0047因其持久的降压作用以及对脑血管系统的未知直接作用，可能对治疗人类中风急性期有益。